论文部分内容阅读
目的:探讨临床应用伊立替康致药品不良反应(ADR)发生的特点及规律,为临床合理用药提供参考。方法:采用回顾性研究方法,收集2011年6月-2015年1月我院应用伊立替康的56例晚期恶性肿瘤患者出现ADR的相关信息,按照性别、年龄、病种、美国东部肿瘤协作组(ECOG)评分、用药情况、ADR累及器官/系统、临床表现以及转归情况等进行描述性统计分析。结果:56例患者发生ADR累及器官/系统以骨髓造血系统所占比例最高(100%),其次为消化系统;其中Ⅰ~Ⅱ级ADR占87.20%,Ⅲ~Ⅳ级ADR占12.80%。64.50%的ADR在用药1周内发生。ADR转归情况方面,85.71%(48/56)的患者给予支持治疗后恢复,继续后续周期化疗,其余8例给予药物减量并对症治疗后好转。结论:伊立替康采用规范化疗方案给药剂量,其临床耐受性良好,ADR多数表现轻微且对症处理均可恢复。应加强对患者随访,防止严重ADR的发生。
Objective: To investigate the characteristics and rules of clinical application of irinotecan-induced adverse drug reaction (ADR) and to provide a reference for clinical rational drug use. Methods: A retrospective study was conducted to collect data on ADR in 56 patients with advanced malignancies treated with irinotecan in our hospital from June 2011 to January 2015. According to gender, age, disease type, (ECOG) score, drug use, ADR involved organ / system, clinical manifestations and outcome of the case were descriptive statistical analysis. Results: The ADR involved organ / system accounted for the highest proportion (100%) of the bone marrow hematopoietic system, followed by the digestive system. Among them, grade Ⅰ ~ Ⅱ ADR accounted for 87.20%, grade Ⅲ ~ Ⅳ ADR accounted for 12.80%. 64.50% of ADR occurred within 1 week of medication. As for the outcome of ADR, 85.71% (48/56) of the patients recovered after supportive therapy and continued the follow-up cycle chemotherapy. The remaining 8 patients were given drug reduction and improved after symptomatic treatment. Conclusion: The irinotecan standard dose of chemotherapy regimen, its clinical tolerability is good, most of ADR showed mild and symptomatic treatment can be restored. Patients should be followed up to prevent the occurrence of severe ADR.